What question did this study set out to answer?

This research aims to highlight the impact and treatment approaches for acute pulmonary embolism (PE).

October 4, 2022JAMA

Acute Pulmonary Embolism

View Full Paper

Ask AI

Bookmark

Population

Patients with acute pulmonary embolism

Design

Review

Authors

YFYonathan FreundUniversité Claude Bernard Lyon 1 FCFleur Cohen‐AubartInserm BBBen BloomQueen Mary University of London

Discussion

Member takes

Implication

Supports guideline-directed DOAC use in stable PE; leaves open need for updated RCTs in high-risk subgroups.

Key Points

This research aims to highlight the impact and treatment approaches for acute pulmonary embolism (PE).
Analysis of PE incidence and mortality rates in the US.
Review of first-line treatments, particularly direct oral anticoagulants.
Discussion of treatment protocols based on systolic blood pressure.
Around 370,000 patients are affected by PE annually in the US.
Estimated annual deaths from PE range between 60,000 to 100,000.
First-line therapies include direct oral anticoagulants, with thrombolysis for specific patients.

Structured PICO

Population

Patients with acute pulmonary embolism

Intervention

Direct oral anticoagulants (apixaban, edoxaban, rivaroxaban, or dabigatran) or thrombolysis (for SBP < 90 mm Hg)

Direct oral anticoagulants are the recommended first-line therapy for acute pulmonary embolism, with thrombolysis reserved for hemodynamically unstable patients.

Cite This Study

Freund et al. (2022) studied this question.

synapsesocial.com/papers/69d83f9b05ee2ba81dbef4d3 https://doi.org/10.1001/jama.2022.16815

Topics

Pulmonary embolism

View Full Paper

Ask AI

Bookmark

Acute Pulmonary Embolism

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Acute Pulmonary Embolism

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider